Keep in touch

Company Engagement

The Medicines Patent Pool’s work depends on partnerships with stakeholders in the HIV field, and its partnerships with patent holding companies are critical to its success.

The MPP has now signed licence agreements with AbbVie, Bristol-Myers Squibb, Roche, Gilead Sciences, ViiV Healthcare [a joint venture of GlaxoSmithKline, Pfizer and Shionogi], and the US National Institutes of Health.

Boehringer-Ingelheim and MSD are in active negotiations with the Medicines Patent Pool.

The Medicines Patent Pool has also sub-licensed to generic manufacturers, who are already beginning to produce and supply HIV medicines at a lower cost. As of December 2014, the MPP had signed sub-licensing agreements with 10 generic manufacturers: to Aurobindo Pharma Limited, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Laurus Labs, Micro Labs, Mylan, Shasun Pharma Solutions and Shilpa Medicare.

The MPP looks forward to continuing dialogue with all relevant patent holders and eligible generic manufacturers and product development partnerships in order to achieve the goal of increasing access to medicines for people living with HIV in developing countries.

The tables below summarise the current status of engagement with patent holders, and with generic manufacturers and product development partnerships.

Patent Holder Engagement

Patent Holder
AbbVie
Boehringer-Ingelheim
Bristol-Myers Squibb
F. Hoffman-La Roche
Gilead Sciences
Merck & Co.
Tibotec/Johnson & Johnson
US National Institutes of Health
ViiV Healthcare
Q4 2014 Q3 2014 Q2 2014 Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013 Q4 2012 Q3 2012 Q2 2012 Q1 2012 Q4 2011 Q3 2011 Q2 2011 Q1 2011 Q4 2010
Agreement for paediatrics signed in November 2014 In negotiations for paediatrics. In negotiations for paediatrics. In negotiations for paediatrics. In negotiations for paediatrics. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 26 January [pdf]. Sent letter on 1 December [pdf]
In negotiations In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 19 January [pdf]. Sent letter on 1 December [pdf]
Agreement signed in December 2013. Agreement signed in December 2013. Agreement signed in December 2013. Agreement signed in December 2013. Agreement signed in December 2013. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 26 January [pdf]. Sent letter on 1 December [pdf]
Agreement signed in August 2013 Agreement signed in August 2013. Agreement signed in August 2013. Agreement signed in August 2013. Agreement signed in August 2013. Agreement signed in August. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Preparing for negotiations. Sent letter on 1 December [pdf]
Licence agreement signed in July 2014.Licence agreement signed in July 2011. Licence agreement signed in July 2014.Licence agreement signed in July 2011. Licence agreement signed in July 2011. In further negotiations. Licence agreement signed in July 2011. In further negotiations. Licence agreement signed in July 2011.
In further negotiations
Licence agreement signed in July 2011. In further negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July 2011. Additional amendment made November 2012 [pdf]. In negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July 2011. Additional amendments made July 2012 [pdf]. In negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July. Amendments made November 2011. In negotiations. Licence agreement signed in July In negotiations. In negotiations. Reply received 14 February [pdf]. Sent letter on 1 December [pdf]
In negotiations. In negotiations. In negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 28 January [pdf] Sent letter on 1 December [pdf]
Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. MPP comments on J&J decision. Not currently in negotiations. J&J decision not to licence at this time. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Reply Received 31 January [pdf]. Sent letter on 1 December [pdf]
Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010
Licence agreement signed in March 2014 for dolutegravir.Licence agreement signed in February 2013 for abacavir. Licence agreement signed in March 2014. Licence agreement signed in March 2014. Licence agreement signed in March 2014. Licence agreement signed in February 2013. In negotiations. Licence agreement signed in February 2013. In negotiations. Licence agreement signed in February 2013. In negotiations. Licence agreement signed in February 2013. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Sent letter on 1 December [pdf]

 

Engagement with Generic Manufacturers

Licences in the MPP
Gilead Sciences
for TDF, FTC, COBI, EVG and QUAD)
(signed Q3 2011)
ViiV Healthcare
for ABC (signed Q2 2013)
Bristol-Myers Squibb
for ATV (signed Q4 2013)
ViiV Healthcare
for DTG 
(signed Q2 2014)
Gilead Sciences
for TAF (signed Q3 2014)
AbbVie
for LPV & r (signed Q4 2014)
Q4 2014 Q3 2014 Q2 2014 Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013 Q4 2012 Q3 2012 Q2 2012 Q1 2012 Q4 2011 Q3 2011
Shilpa Medicare signs a sub-licence. MedChem sub-licence terminated. Shasun signs a sub-licence Hetero Labs signs sub-licence, and Laurus Labs signs a sub-licence Emcure Pharmaceuticals signs sub-licence. Aurobindo Pharma Limited signs sub-licence. MedChem signs sub-licence [pdf]. Licence agreement with Gilead signed.
Aurobindo signs a sub-licence. Licence agreement with ViiV Healthcare signed. N/A (licence signed Q1 2013) N/A (licence signed Q1 2013) N/A (licence signed Q1 2013) N/A (licence signed Q1 2013) N/A (licence signed Q1 2013) N/A (licence signed Q1 2013)
Aurobindo and Emcure sign a sub-licence Desano signs a sub-licence   N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A
Cipla, Hetero Labs. Laurus Labs, Micro Labs and Mylan sign a sub-licence  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A
Aurobindo, Cipla, Desano, Emcure, Etero and Laurus Labs sign a sub-licence  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A
 N/A N/A N/A N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A

 

This page is also available in: French, Spanish